Active not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

Lead sponsor

Eli Lilly and Company

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

100

Recruiting sites

Estimated enrollment

974

Study population

Hypertension, Obesity / overweight

Eligibility highlights

•BMI ≥25

Primary endpoint

•Number of Participants Allocated to Each ISA

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06948422

Org study ID27223

Timeline

Milestones

Study first posted2025-04-29actual

Study start2025-04-30actual

Last update posted2026-05-29actual

Primary completion2027-09estimated (month precision)

Study completion2027-09estimated (month precision)

Assets

Investigational agents

Orforglipron

Who this study enrolls

HypertensionObesity / overweight

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Has systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg (if DBP criteria alone is met, SBP must be ≥130 mmHg) at screening (Visit 1).

•Has SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg (if DBP criteria alone is met, SBP must be ≥130 mmHg) at week 0 (Visit 3).

•Untreated for hypertension, or on stable antihypertensive medications ≥ 30 days prior to Visit 1.

•Have a body mass index (BMI) ≥ 25 kg/m².

Exclusion criteria

•Has SBP ≥170 mmHg and/or DBP ≥110 mmHg at Visit 1 or at Visit 3.

•Has known secondary causes of hypertension

•Have heart failure with reduced ejection fraction (HFrEF) diagnosis

•Have had any of the following conditions within 90 days prior to screening.

-hospitalization for hypertension or for congestive heart failure

-acute coronary syndrome or acute myocardial infarction, or

-cerebrovascular accident (stroke).

•Have type 1 diabetes (T1D)

•Have acute or chronic hepatitis, including a history of autoimmune hepatitis

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Number of Participants Allocated to Each ISA

Time frame:Week -8 to Week 0

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.